Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765648 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
A Phase 4 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
NCT00765648 is a Phase 4 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 226 participants.
The verdict
NCT00765648, a Phase 4 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
Interventions
- DRUG Labetalol
- DRUG nicardipine intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765648
The ClinicalTrials.gov registry entry for NCT00765648 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Labetalol is the first listed.
NCT00765648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765648 about?
NCT00765648 is a clinical study titled "Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department". The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
What is the current status of trial NCT00765648?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2008-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00765648?
The interventions under investigation include: Labetalol (DRUG), nicardipine intravenous (DRUG).
Who is sponsoring clinical trial NCT00765648?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.